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Supplementary Methods
Model Structure
Summary
The framework of the model used is based on a traditional SI (susceptible-infected) model, with an additional compartment T representing the population undergoing treatment ( Figure 1A ). Each of these compartments is stratified in 4 dimensions: (1) 3 PWID strata (non-, current, and ex-PWID; Figure 1C ); (2) 5 liver disease state strata (none/mild liver disease or F0-F1, moderate liver disease or F2-F3, compensated cirrhosis or F4, decompensated cirrhosis, and hepatocellular carcinoma; Figure 1B ); (3) 9 age group strata (<15, 15-17, 18-24, 25-29, 30-34, 35-39, 40-44, 45-50 , and 50+; Figure 1C ); and (4) 2 gender strata (male and female). The full model therefore contains 810 equations representing each possible combination of compartments. The model was initialized in 1900 with a population size of 4 million, all susceptible, non-PWID, and with no liver disease, distributed equally across gender and age compartments.
The model progresses as follows. Each year, B individuals are born into the susceptible category in the youngest age group, equally divided between males and females. These individuals age at agegroup specific rates α and die at age and gender-specific rates μ. Susceptible individuals become infected at a force of infection λ according to the ratio of infected to susceptible population sizes and PWID status, with a rate of transmission β for the whole population, and an additional rate of transmission θ for current PWID, with the force of infection also accounting for the coverage of harm reduction interventions. The infected population starts treatment at rate σ and completes treatment at rate ω, either entering the susceptible or infected populations according to the cure rate π. Non-PWID transition to PWID at gender-and age-specific rates ψ and PWID cessate from injecting at age-specific rates φ and have an additional drug-related death mortality ratio ν. If infected, the population in the none/mild liver disease state progress through moderate liver disease to compensated cirrhosis at rates γ, and do not progress through these states if cured. Progression from compensated cirrhosis to decompensated cirrhosis or hepatocellular carcinoma (HCC) occurs at rates χ, with reduced progression rates for those that are no longer infected due to successful treatment. HCV-related death occurs from decompensated cirrhosis and hepatocellular carcinoma at rates ζ. Inflows and outflows from each compartment are due to birth ( =1 ) and death ( , , ), disease progression ( , ), aging ( ), recruitment ( =1, ( )) and cessation ( =2 ) of injecting drug use (IDU), treatment ( ( )), and cure ( , ( )). The treatment parameter ( ) was calculated as the ratio of number of treatments implemented per infected individuals in the model at each time point (see Treatment section below). HCV transmission occurs through the force of infection ( ( )), as described below.
Equations
The basic structure of the model is therefore:
The force of infection ( ) is determined by the degree of assortative mixing ( ) amongst PWID by age group (<30, ≤ 4 versus 30, ≥ 5), the impact and coverage of harm reduction measures (NSP and OST, ( )), general population HCV transmission parameter β, reduction in general population transmission parameter ( ), and PWID HCV transmission parameter θ, where ( ) = ( ) + ( ) + ( ):
For all non-PWID:
For old PWID:
Where in the base case (high intervention impact; see Impact of Harm Reduction section below for more details) the impact of OST and NSP are determined by OST coverage ( ( )), OST effectiveness ( ), and NSP-associated impact ( ):
In the alternative scenario (low intervention impact), NSP is determined by coverage ( ( )) and effectiveness ( ), such that:
Parameter Definitions
Parameters used in the model are either fitted (see Model Calibration section and Supplementary Tables 2-5) or input as single values, as described below. All rates are annual.
Demographics
The annual number of births =1 is assumed to be equal for males and females and to remain constant over time; this parameter is fitted to achieve the target population size with a prior range from 51,000 to 62,000. Aging ( ) rate is defined as the inverse of the duration spent in each category (Supplementary Table 1 ). Table 2 ).
Injecting drug use
Recent estimates from 2007-2014 suggest a stable PWID population in Georgia of about 50,000 1 , however, data from 1998-2015 suggest an aging PWID population, likely due to reduced initiation of injecting ( Supplementary Figure 1 ). To account for the changing dynamics of IDU in Georgia, we assumed a transient peak in the initiation of IDU, allowing considerable uncertainty in when this occurred and its magnitude. Recruitment to injecting drug use ( ) is assumed to start in 1960, which is the first year of reported injecting in all available biological and behavioural surveillance (BBS) surveys, scale up in year 2 by 1 , and decline in year 2 + ∆ by 2 (Supplementary Table 2 ). Therefore for non-PWIDs (k=1), the rate of recruitment to IDU is: . Proportions of PWID recruited into each age group were calculated from the distribution of ages in which PWID reported starting injecting within the BBS. We assume that once an individual has cessated injecting they do not restart.
The rate of cessation from injecting ( =2 ) is fit individually to three age groups of PWID, with separate rates for age groups <29 years, 30-49 years, and 50+ years. The model also allowed for the possibility of assortative 'like-with-like' mixing when young (<30 years) and older (>30 years) PWID form transmission contacts, varying between random mixing across these age groups to preferential mixing only between PWID of the same age group, according to the fitted parameter M (Supplementary Table 2 ).
HCV transmission
We fit separate transmission parameters for transmission of HCV in the general population ( ) and PWID ( ), which represent the annual effective contact rates of transmission within the force of infection equation above (Supplementary Table 3 ). The rates of transmission are fit to prevalence of chronic infection so spontaneous clearance of infection is not explicitly modelled. Hepatitis C is introduced to the model in 1960, when IDU is assumed to have started, with any cases of hepatitis C prior to this time assumed to no longer be alive. To generate a rapid increase in infection amongst PWID, hepatitis C is seeded in the model with a 10% annual rate of infection for susceptible PWID < 30 years old in the first five years after 1960.
HCV transmission in the general population is assumed to decline over time, with a reduction at time point 3 , by the ratio , due to increasing awareness of blood-borne virus transmission routes leading to reductions in medical risks (Supplementary Table 3 ). We assume this coincides with restructuring of the health system and the introduction of new regulations including donor blood screening from 1997 2,3 . HCV transmission due to IDU changes over time through harm reduction measures as described in the next section.
Impact of Harm Reduction
Harm reduction measures were introduced in Georgia in the early 2000s, including voluntary counselling and testing, needle and syringe provision (NSP), and opioid substitution therapy (OST); NSP was introduced in 2001 and OST in 2005 with both gradually increasing over time 4, 5 . The impact of NSP and OST at reducing HCV transmission have been estimated in a recent global Cochrane review 6 . We use the global effectiveness estimate from this review for the OST effectiveness parameter , with two alternative methods for estimating the effectiveness of NSP ( Supplementary Table 4 ).
Initially, we fit a low intervention effect model scenario which uses values for the impact of NSP from the Cochrane review 6 , and reported NSP coverage 5 , which is presented in the sensitivity analysis. Model calibration scenarios had to agree with current epidemic patterns amongst PWID and the general population. However, the low intervention effect model did not capture the observed decline in hepatitis C prevalence in young PWID, instead fitting a relatively low hepatitis C incidence in PWID through the whole time period. Therefore, a new structure for the impact of NSP, the high intervention effect model, was developed and fit to the observed halving of hepatitis C prevalence in young PWID between 2002 and 2015. The high intervention effect model is the primary scenario presented in the main text. This calibration freely varies the efficacy of NSP interventions in the model to ensure it closely agreed with the observed large reduction in the prevalence of hepatitis C amongst young PWID over the last 20 years (decreased from 62% in 1997 to 29% in 2015, Supplementary Figure 2 ). To match this, we fit an initial reduction in PWID transmission in 2002, when a large project on prevention of HIV/AIDS was initiated 7 . We assume the initial change in PWID HCV transmission ( 2002 ) varies linearly over 10 years towards an independently sampled value for reduction in PWID transmission which is constant from 2012 onwards ( 2012 ). Finally, we fit the model to the same summary statistics without allowing a peak in PWID recruitment, in order to evaluate the importance of this peak in producing model fits.
When looking at hepatitis C sero-prevalence data across cities with repeated BBS PWID surveys, the overall prevalence of hepatitis C amongst PWID in Batumi and Tbilisi increased by 16% (relative increase) for 2006-2015, and by 29% in Kutaisi for 2007-2015; the more conservative increase from the larger populations in Batumi and Tbilisi was used for model fitting.
Liver disease progression
Progression through liver disease states occurs after HCV infection, and is modelled according to Metavir stages (F0-F4) 8 . The population in the none/mild liver disease state (F0-F1) transitions to moderate liver disease (F2-F3) at annual transition probability 1 , and then to compensated cirrhosis (F4) at rate 2 . After hepatitis C is cured through treatment, it is assumed that susceptible individuals do not continue to progress through liver disease from the mild or moderate liver disease states. After reaching compensated cirrhosis, progression to decompensated cirrhosis occurs at annual transition probability 3 , with progression reduced by ratio 1 for HCVsusceptible individuals. Similarly, those with compensated or decompensated cirrhosis progress to HCC according to parameter 4 , which is scaled by 2 for HCV-susceptible individuals. HCVrelated death occurs only from states of decompensated cirrhosis ( 4 ) and hepatocellular carcinoma ( 5 ). The values were estimated from published studies [9] [10] [11] , with the uniform prior range representing the 95% confidence intervals of reported transition probabilities (Supplementary Table 5 ). The parameters were then fitted in the model fitting process, however, the posteriors were expected to remain similar to the priors as there were no summary statistics likely to restrain them.
Treatment
Prior to the elimination program, between 2011 and 2015 a total of 1,685 patients in Georgia received treatment with pegylated interferon and ribavirin 12 ; we do not include these treatments in the model. The elimination program was initiated on 28 April 2015, with treatment initially prioritized to patients with advanced liver disease 13 . Treatment is introduced in the model from May 2015 using monthly treatment numbers from the elimination program data, allocated by liver disease state (Supplementary Table 7 ). Liver disease was measured through transient elastography or by FIB-4 8, 14 , with cirrhosis defined as F4 or FIB-4 > 3.25.
From May 2015 to March 2016, sofosbuvir and ribavirin were used to initiate 7,097 patients on treatment, achieving per-protocol sustained virologic response (SVR) of 80.4%. From April 2016 to February 2019, sofosbuvir/ledipasvir was used to initiate 47,216 patients, with a per-protocol SVR of 98.3% (Supplementary Table 7 ). The latter SVR rate is used for projected treatments.
The treatment parameter ( ) is calculated from May 2015 to February 2019 according to the monthly number of treatments initiated in each liver disease state (mild/none, moderate, cirrhosis, decompensated cirrhosis; Supplementary Table 7 ). At each time point in the model, for each liver disease category the monthly treatment number is converted to an annual treatment number and divided by the number of individuals in all of the corresponding infected liver disease states (regardless of PWID status, age, or gender) to get the proportion of individuals to treat, which is assumed to be 0 if there are no eligible individuals. These proportions are then multiplied by the number of individuals in each infected compartment to calculate the annual number of treatments that are initiated at that time point. From March 2019 onwards, at each time point the annual number of treatments is allocated proportionally across all infected individuals with eligible liver disease states (ie excluding hepatocellular carcinoma) regardless of PWID status, age, or gender.
In the sensitivity analysis, alternative strategies for the distribution of treatment were explored, in which PWID were excluded from treatment or targeted for treatment, or 80% of patients with compensated cirrhosis are treated in each year. When PWID are excluded from treatment the number of treatments eligible for treatment excluded those in the current PWID category, such that the same number of treatments are distributed among a smaller population of infected individuals. When PWID are targeted for treatment the proportion of PWID treated is calculated to be double the proportion of non-PWID treated, such that the same number of treatments are allocated. When patients with cirrhosis are targeted for treatment, initially 80% of patients with compensated cirrhosis are allocated treatments, and then the remaining number of treatments are allocated proportionally across all remaining eligible categories.
For each scenario, the number of treatments required to reach a 90% reduction in adult hepatitis C prevalence from 2015 to the end of 2020 was fitted for each parameter set using the Matlab function lsqnonlin. Model runs which failed to fit were excluded from further analysis; between 0 and 3 parameter sets failed to fit in each scenario evaluated.
Adjusted SVR
In the baseline model, we use an adjusted SVR rate for pre-cirrhotic and cirrhotic treated patients. These rates assumed the per-protocol SVR rate for all individuals that achieved the end of treatment (78% of treatment initiates) and assumed a reduced SVR rate based on studies of shorter treatment regimens for those individuals that did not achieve the end of treatment due to being lost to follow up during treatment 15 . The reduced SVR rate for those lost to follow up was calculated by fitting a logarithmic trend line to mean SVR by treatment durations of 4, 6, 8, and 12 weeks [15] [16] [17] (Supplementary Figure 3) , and integrating this function to determine the area under the curve of 6.6 cure-weeks. Assuming that patients are equally likely to be lost to follow up at any time point of treatment, we calculated the average cure rate over 12 weeks of treatment as 0.55.
Model Calibration
A version of Markov Chain Monte Carlo Approximate Bayesian Computation (MCMC-ABC) was used to fit the model by constraining prior ranges of model parameters based on fit to summary statistics from the calibration data (Supplementary Table 6 ). We used the package EasyABC in R 18, 19 with the Wegmann method 20 , which uses a partial least-squares transformation to weight the summary statistics to reduce the computation time needed to approximate the posterior. The model was initialized with 30,000 calibration steps and the best 0.5% of calibration simulations used to set the tolerance level. The chain was then run until 70,000 parameter sets were accepted using 1 standard deviation as the width for the proposal range of new parameter values at each step, and with 1 step between samples. All prior distributions were uniform. Parameter sets accepted in the first phase were then filtered as described in the main text.
Hepatitis C Incidence in PWID
Unpublished data on incident HCV infections in Georgia were received from M. Aladashvili of the Infectious Diseases, AIDS, and Clinical Immunology Research Center in Tbilisi, Georgia. The studies in which the data were collected have been partially published 21, 22 .
Patients were recruited from the cities of Tbilisi, Batumi, and Poti, and patients were enrolled over time during two studies from 1997-1999 and 2000-2001. In the first study, 926 PWID were recruited and evaluated with a baseline assessment and two follow ups at 6 month intervals. In the second study, 469 PWID who had participated in the first study were recruited again, and 114 new PWID were recruited, and included up to three evaluations at 6 month intervals as in the previous study. At each visit participants were tested for HIV and HCV antibodies if they had not already had a positive test at a previous visit.
Incidence was calculated for the period 1997-2001. There were 102 incident cases of hepatitis C in 423 individuals anti-HCV negative at baseline and followed up for 698 person years, resulting in an incidence rate of 14.6 (12.0 -17.7) per 100 person years. Supplementary Table 1 Age-varying demographic parameter rates used in the model of Hepatitis C in Georgia. Death rates adapted from the WHO Global Health Observatory data repository life tables for the country of Georgia for 2010-2015 (http://apps.who.int/gho/data/view.main.60610?lang=en). Hazard ratio of progression to DC after SVR ratio 0.03 -0.20 10 2 Progression compensated cirrhosis or decompensated cirrhosis to HCC annual transition probability 0.0016 -0.039 9 2 Hazard ratio of progression to HCC after SVR ratio 0.16 -0.35 11 1 Progression decompensated cirrhosis to death annual transition probability 0.11 -0.15 9 2 Progression HCC to death annual transition probability 0.37 -0.49 9 *DC: decompensated cirrhosis; SVR: sustained virologic response; HCC: hepatocellular carcinoma Supplementary Table 6 Summary statistics used to fit model of Hepatitis C in Georgia. Antibody prevalence from PWID serosurveys was converted to chronic prevalence by using multiplicative factor of 72% based on chronic prevalence among HCV antibody positive in 2015 general population serosurvey. 
Supplementary Tables

Supplementary Figures
Supplementary Figure 1 Histograms of demographics of people who inject drugs in Georgia compiled from behavioral surveys and Integrated Biological and Behavioral Surveillance surveys 4, 5, 21, 22, 25, 29 , showing current age distribution at time of each survey, reported age at first injection, year first injected, and calculated duration injecting.
Supplementary Figure 2
Hepatitis C prevalence (mean and 95% confidence intervals) in people who inject drugs in Tbilisi, Georgia over time 4, 5, 21, 22, 25, 29 , grouped by age (left plot; < 30 years versus ≥30 years old) or duration of injecting (right plot; <5 years versus ≥5 years injecting drug use). 
Supplementary Figure 11
Distribution of model fits (box plots) to target summary statistics (red lines) for parameter fitting scenario in which there is no peak in initiation of injecting drug use; A total of 156 parameter sets were accepted in this case. By comparison to the baseline model fits shown in Supplementary Figure 6 , this approach does not achieve good fits to the age distributions of people who inject drugs (PWID) or differences in hepatitis C prevalence by age amongst PWID. PWID: people who inject drugs; CHC: chronic Hepatitis C. 
